問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳卓鍇

Recruiting

List

21Cases

2023-10-02 - 2030-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-07-01 - 2026-01-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-03-01 - 2027-02-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting16Sites

2023-03-01 - 2027-04-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2025-08-01 - 2031-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-12-15 - 2028-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-03-17 - 2024-05-02

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2025-10-01 - 2030-06-30

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2023-12-15 - 2028-06-30

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

  • Condition/Disease

    Transthyretin amyloid cardiomyopathy

  • Test Drug

    ALXN2220

Participate Sites
5Sites

Recruiting5Sites

2018-10-24 - 2024-03-31

Phase III

SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity

  • Condition/Disease

    Obesity

  • Test Drug

    Semaglutide B 3.0 mg/mL PDS290 or Semaglutide placebo

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB